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Combination antiretroviral therapy controls but does not cure HIV-
1 infection because a small fraction of cells harbor latent viruses
that can produce rebound viremia when therapy is interrupted.
The circulating latent virus reservoir has been documented by a
variety of methods, most prominently by viral outgrowth assays
(VOAs) in which CD4+ T cells are activated to produce virus in vitro,
or more recently by amplifying proviral near full-length (NFL) se-
quences from DNA. Analysis of samples obtained in clinical studies
in which individuals underwent analytical treatment interrup-
tion (ATI), showed little if any overlap between circulating latent
viruses obtained from outgrowth cultures and rebound viruses
from plasma. To determine whether intact proviruses amplified
from DNA are more closely related to rebound viruses than those
obtained from VOAs, we assayed 12 individuals who underwent
ATI after infusion of a combination of two monoclonal anti–HIV-
1 antibodies. A total of 435 intact proviruses obtained by NFL
sequencing were compared with 650 latent viruses from VOAs
and 246 plasma rebound viruses. Although, intact NFL and out-
growth culture sequences showed similar levels of stability and
diversity with 39% overlap, the size of the reservoir estimated
from NFL sequencing was larger than and did not correlate with
VOAs. Finally, intact proviruses documented by NFL sequencing
showed no sequence overlap with rebound viruses; however, they
appear to contribute to recombinant viruses found in plasma
during rebound.
HIV | latent reservoir | sequencing | analytical treatment interruption
During the HIV-1 infection cycle, viral DNA is inserted in theCD4+ T cells as a provirus and is then actively transcribed to
produce new virions. In the vast majority of infected cells, this
burst of HIV-1 production leads to cell death by apoptosis or
pyroptosis (1). A far less frequent alternative fate is for the
provirus to be suppressed and to become latent (2). Upon
treatment interruption, latent proviruses are stochastically acti-
vated leading to rebound viremia and the requirement for life-
long therapy for HIV-1 infection (3).
Although numerous methods have been evaluated to measure
the latent reservoir, viral outgrowth assays (VOAs) are considered
to be the gold standard (2, 4). In this assay, infected donor CD4+
T cells are activated in vitro to induce HIV-1 production in the
presence of uninfected recipient CD4+ T cells. When performed
at limiting dilution, and combined with sequence analysis of the
emerging viruses, VOAs can yield both quantitative and qualita-
tive information about the latent reservoir (5–7).
When the reservoir is assayed by VOAs, individuals that have
achieved viral suppression on antiretroviral therapy (ART) are
typically found to harbor 1 between 105–106 circulating CD4+
T cells that contain replication competent latent proviruses (8).
Longitudinal studies have estimated that the half-life of the latently
infected CD4+ T cells in the HIV-1 reservoir is 44 mo (9, 10).
However, there are several caveats to interpreting the results of the
VOAs: (i) The assay is highly variable and any difference of less
than sixfold is not considered to be significant (10); (ii) a single
round of stimulation captures only a fraction of the latent cells that
can be reactivated (6); (iii) individual latent cells differ in their re-
quirements for reactivation (11); (iv) VOAs are typically performed
on cells derived from blood and this compartment may not be
representative of the entire latent reservoir (12); and (v) the re-
quirements for reactivation in vitro and in vivo may differ signifi-
cantly (13, 14).
Sequencing intact viral genomes from limiting dilution CD4+
T cell DNA samples is a recently developed alternative method
to document the HIV-1 reservoir (11, 15). An advantage of this
sequencing method is that it does not require latent virus reac-
tivation in vitro. However, it too is subject to the same sampling
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caveats as VOAs, and the additional question of whether intact
proviruses contribute to rebound viremia during treatment
interruption.
A small number of intact proviral sequences obtained by near
full-length (NFL) sequencing have been compared with VOAs
and rebound viruses in a clinical trial where individuals un-
derwent analytical treatment interruption (ATI) after mono-
therapy with the 3BNC117 monoclonal anti–HIV-1 antibody
(16). To further examine the relationship between proviruses
obtained from circulating CD4+ T cells by NFL sequencing and
the viruses that emerge from the reservoir during treatment in-
terruption, we analyzed samples from 12 individuals enrolled in a
clinical trial that involved ATI after infusion of a combination of
two broadly neutralizing monoclonal antibodies (bNAbs) (17).
Results
3BNC117 and 10-1074 are broad and potent monoclonal anti–
HIV-1 antibodies that target independent nonoverlapping sites
on the HIV-1 envelope spike (18, 19). The combination of the
two antibodies was administered to 15 individuals undergoing
ATI, 2 d before, and 3 and 6 wk after ATI (Fig. 1A) (17).
Leukapheresis was performed 2 wk before and 12 wk after ATI,
and plasma was obtained for single genome analysis (SGA) at
the time of rebound.
NFL proviral genomes were amplified from DNA extracted
from purified CD4+ T cells obtained from the two leukapheresis
samples from nine individuals that maintained viral suppression
for >12 wk after ATI, including two that remained virologically
suppressed during the entire observation period (>30 wk, par-
ticipants 9254 and 9255) (11, 17, 20). A single preinfusion sample
was also available for three additional individuals that experi-
enced viral rebound within 12 wk of ATI (participants 9245,
9249, and 9253) (17). Qualitative and quantitative viral out-
growth assay (Q2VOA) was performed on all of these samples
(17). Participant 9254 was excluded from the quantitative part of
the analysis because of inadequate sample availability.
HIV-1 DNA content was initially measured by performing
limiting dilution gag PCR (Fig. 1B) (11). NFL genomes were
amplified from DNA aliquots containing a single HIV-1 genome
(Fig. 1B). To increase efficiency, only samples containing full-
length env fragment were further processed and subjected to
sequence analysis (Fig. 1B).
Overall, the amount of HIV-1 DNA in CD4+ T cells in cir-
culation did not change significantly during the observation pe-
riod. On average gag+ proviruses were found at a frequency of
942 and 841 out of 106 CD4+ T cells at the preinfusion and week-
12 time points, respectively (Fig. 1C and SI Appendix, Table S1).
Although individual participants showed some variation in the
frequency of gag+ proviruses at the two time points, the degree of
variation was consistent with 2.5-fold variability in the assay (Fig.
1C and SI Appendix, Table S1).
Defective HIV-1 proviruses frequently carry deletions in env
(11). We found that the median number of proviruses containing
full-length env was 21 times lower than gag+ proviruses for both
preinfusion and week-12 time points (Fig. 1C and SI Appendix,
Table S1). Proviruses with a near full-size HIV-1 genome were
found at a still lower frequency of 20 and 11 out of 106 CD4+
T cells at the preinfusion and week-12 time points, respectively
(Fig. 1C and SI Appendix, Table S1). The difference between the
number of CD4+ T cells containing env and a near full-size HIV-
1 genome is expected because a fraction of defective proviruses
retains intact env (21). Similar to gag or env, there was no sig-
nificant difference in the frequency of cells containing near full-
size HIV genomes between the two time points (Fig. 1C and SI
Appendix, Table S1).
To determine the frequency of intact proviruses in circulating
CD4+ T cells, we sequenced all near full-size HIV-1 proviruses
and counted only those with intact reading frames, packaging
signals, and major splice donors (MSDs). Intact proviruses were
found at a median frequency of 2.8 out of 106 CD4+ T cells at
both time points, which is 5.9- and 6.9-fold lower than the
number of proviruses containing near full-size HIV-1 genomes at
the preinfusion and 12-wk time points, respectively (Fig. 1C and
SI Appendix, Table S1). Overall, on average only 1 out of 336 or
300 gag+ proviruses were intact at the preinfusion and week-
12 time points. Nevertheless, there was a positive correlation
between the number of intact and gag+ proviruses, and also be-
tween intact and near full-size proviruses (P = 0.042, r =
0.471 and P = 0.019, r = 0.532, respectively, Fig. 1D).
The difference between the number of proviruses with near
full-sized genomes and intact sequences can be explained by a
combination of hypermutation, small insertions and deletions
(indels), and defects in the packaging site and/or major splice
donor. The relative contribution of each of these differed sig-
nificantly between individuals but was similar at the two time
points for each participant. For example, packaging site and
major splice site defects were dominant in participant 9252, but
these defects were not found in participant 9241 (Fig. 2A and SI
Appendix, Table S2). Overall, hypermutation accounted for
∼55% of all defective near full-sized genomes, but this too varied
between individuals. After hypermutation, the next most fre-
quent source of defective proviruses was packaging site and/or
major splice donor mutation or deletion at an overall rate of
∼27%, with the remainder accounted for by indel/nonsense
mutations (SI Appendix, Table S2).
Although there were hotspots for mutations that pro-
duced premature stop codons, most of which correspond to
APOBEC3 target sites, hypermutations were found throughout
the HIV-1 genome (Fig. 2B, Upper). On average, each individual
hypermutated sequence carried 54 in-frame stop codon mu-
tations. In contrast, it was unusual to find multiple indels in a
single sequence. In addition, the location of the indels did not
appear to correspond to the APOBEC3 mutation hotspots
(Fig. 2B, Lower).
Compared with NFL sequencing, Q2VOA measurements
performed on the same samples showed fewer infectious units
per million (P < 0.001) (SI Appendix, Fig. S1 and Table S1). The
median number of inducible viruses enumerated by Q2VOA was
8.5- and 8.4-fold lower than the NFL measurement at the pre-
infusion and week-12 time points, respectively (Fig. 1C and SI
Appendix, Table S1). As noted by others (21), the difference
between the two measurements in individual participants varied
and there was no direct correlation between the two measure-
ments (Fig. 1D and SI Appendix, Table S1). For example, when
both time points are taken together for participant 9247, 0.87%
of gag+ proviruses contain an intact provirus, but only 0.004% of
gag+ proviruses have a virus that emerges in the Q2VOA (SI
Appendix, Fig. S2). In contrast, in participant 9255, the per-
centage of gag+ proviruses that contain intact provirus is only two
times higher than the percentage of viruses that emerges in the
Q2VOA (0.26% and 0.13%, respectively) (SI Appendix, Fig. S2).
Although the size of the reservoir estimated by the two methods
was different, the overall diversity of HIV-1 sequences was
similar (P = 0.79) (SI Appendix, Fig. S3). Neither the number of
intact proviruses at the preinfusion time point nor the change in
the number of intact proviruses between the two time points
correlated with time to rebound (P = 0.69 and 0.07, respectively).
Q2VOA analysis revealed that 56% of the viruses found at the
preinfusion and week-12 time points belonged to expanded
clones (17). A comparable number of clonal viruses was also
found among the intact NFL sequences (53%, SI Appendix,
Table S3). Overall, 39% of the all intact NFL sequences were
identical to Q2VOA sequences (Figs. 3 and 4 A and B and SI
Appendix, Fig. S4). Similar to Q2VOA, identical expanded intact
NFL clones appeared at both time points in nearly all of the
individuals tested, but the relative representation of each of the
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clones varied. Large expanded clones that dominated in Q2VOA
in participants 9252, 9254, and 9255 were also dominant in intact
NFL sequences in those individuals. In contrast, there was far
less overlap between the two assays in individuals like 9242, 9243,
and 9244 that have a more diverse latent reservoir (Figs. 3 and 4
A and B and SI Appendix, Fig. S4). Consistent with these ob-
servations there was a strong positive correlation between the
percentage of env clonality and overlap between Q2VOA and
intact NFL sequences (P = 0.0015, r = 0.808, SI Appendix,
Fig. S5).
When assayed by VOA, the relative distribution of clones is
dynamic in that the number of cells that reactivate a specific
latent provirus frequently differs between time points (17, 22).
For example, individuals 9241, 9254, and 9255 show significant
changes in clonal distribution by Q2VOA. In contrast, NFL se-
quencing failed to reveal significant changes in any of the indi-
viduals assayed (Fig. 3). The disparity between the two assays is
likely due in part to the requirement for reactivation in VOAs
and difference in the number of CD4+ T cells assayed by the two
methods (average 24-fold higher for Q2VOA, SI Appendix,
Fig. S6).
To examine the relationship between circulating intact provi-
ruses documented by NFL sequencing and plasma rebound
viruses, we compared env sequences obtained from 10 individ-
uals that underwent ATI after infusion of a combination of
broadly neutralizing antibodies. The selected individuals in-
cluded the seven that had two leukapheresis and rebounded late
(>12 wk after ATI), and three that rebounded early due to
preexisting antibody resistance (17). Although all of the rebound
viruses were >96% identical to at least one sequence from the
reservoir, we did not find a single instance of 100% env identity
among 435 intact NFL sequences and 246 rebound viruses
obtained by SGA (Fig. 4 A and B and SI Appendix, Fig. S4).
To determine whether rebound sequences could have evolved
by accumulating mutations during ATI, we used a mathematical
model to simulate this process (16). We found that only 12 out of
246 rebound sequences (SI Appendix, Fig. S7, blue bars) could be
accounted for by mutation of reservoir sequences (SI Appendix,
Fig. S7, gray bars). Consistent with a previous report, the observed
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distance between latent and rebound viruses decreased in 205
out of 246 rebound sequences when the possibility of recombi-
nation was included (SI Appendix, Fig. S7, yellow bars). Using the
3SEQ recombination algorithm (mol.ax/software/3seq/), we found
that 48% of the rebound viruses could be recombinants between
intact NFL and/or Q2VOA proviruses. For example, in partici-
pants 9249, 9253, 9244, and 9246, the “parent” env sequences
were either from intact NFL or Q2VOA, and in participant 9245,
the parent sequences were uniquely from intact NFL (Fig. 4C).
In addition, rebound viral sequences also served as parents for
recombination (Fig. 4C). There was no discernible pattern to the
recombination events. However, among the 12 latent parent
sequences, there was only one instance in which the parent virus
was part of an expanded clone. Finally, the sensitivity to bNAbs
was comparable between recombinants and other rebound
viruses. In conclusion, some of the rebound viruses that emerge
during ATI appear to be recombinants derived from the
circulating latent reservoir characterized by Q2VOA or NFL
sequencing.
Discussion
Long-lived integrated proviruses represent the key barrier to
HIV-1 cure (2). Several different assays have been used to try to
characterize and measure the latent reservoir, most prominently
nucleic acid based and viral outgrowth assays (23). Although
these assay have produced a great deal of information on
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latent proviruses found in circulating CD4+ T cells, the precise
relationship between these viruses and those that emerge in
HIV-1–infected individuals during ART interruption has not
been defined. To add to the dataset that addresses this important
question, we have compared 435 intact NFL proviruses obtained
from circulating CD4+ T cells by NFL sequencing to 650 Q2VOA
and 246 plasma rebound viruses from individuals enrolled in a
clinical trial of combination immunotherapy with broadly neu-
tralizing antibodies 3BNC117 and 10-1074 (17).
Overall Q2VOA and NFL sequencing yield overlapping and
similarly diverse sets of viruses. As might be expected, the over-
lap between the sequences obtained by the two methods was
most significant in individuals with a more clonal and less diverse
reservoir. One of the differences between the two methods was
that clones obtained from NFL sequencing appeared to be more
stable between the two time points. For example, participants
9241, 9254, and 9255 showed significant clonal variation by
Q2VOA not found by NFL sequencing. These qualitative dif-
ferences could be due to stochastic activation of latent viruses in
vitro and/or to sampling error because the total number of cells
sampled in the NFL sequencing was on average 24-fold lower
than in Q2VOA.
There were also significant quantitative differences between
proviruses enumerated by NFL sequencing and Q2VOA. In the
individuals assayed, Q2VOA underestimates the size of the la-
tent reservoir by an average of 8.5-fold, but there is tremendous
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variation between individuals ranging from 1.4- to 915-fold. This
finding is consistent with previous reports showing that VOA
underestimates the size of the latent reservoir, and that there is
no clear correlation between the two methods (6, 11, 21). These
quantitative differences could be accounted for if some of the
intact proviruses documented by NFL sequencing cannot be
reactivated or are simply defective in some way that has not been
detected. However, in all instances reported to date, proviruses
reconstructed based on intact NFL sequences were productively
infectious in vitro (11). An alternative and nonexclusive expla-
nation for the disparity between the measurements is that the
requirements for latent virus reactivation are both cell or stim-
ulus specific such that only a seemingly random fraction of all
latent viruses are reactivated by a particular stimulus in vitro (6).
The vast majority of near full-sized genomes we sequenced,
83% were defective due to hypermutation or mutant packaging
signals or major splice donors. Defective proviruses can pro-
duce protein products that are targeted by cytotoxic T cells
(24); however, we found little fluctuation in the number of
these proviruses or the types of defects they carry between two
time points.
Three recent clinical studies that included ATI after bNAb
infusion evaluated the relationship between circulating latent
viruses documented by VOA and rebound viruses (16, 17, 25). A
total of 1,411 VOA and 682 rebound viruses were characterized
from 30 individuals undergoing ATI. A small number of intact
NFL sequences were also obtained by Cohen et al. (16). In all,
there were only 13 instances of overlap between latent and re-
bound viruses and this occurred in only 4 of the 30 individuals.
Although there are antibody-dependent selective changes in
the rebound viruses, viral sensitivity to the bNAb and time to
rebound did not influence the results (16). In addition, Cohen
et al. found that the differences between the latent and re-
bound viruses could not be accounted for by HIV-1 mutation,
but instead, it appeared that rebound viruses were frequently
composed of recombinants between viruses emerging in
Q2VOA (16).
Our results comparing 435 env sequences from intact provi-
ruses with 246 plasma-derived rebound envs add to this growing
body of data. Although proviruses found in circulation can
contribute to rebound (26), we did not observe direct overlap
between intact NFL and rebound sequences. Instead, 48% of all
rebound env sequences in 10 individuals could be accounted for
in part by recombination when both intact NFL and Q2VOA
sequences are taken into account. This is likely to be an un-
derestimate since we are only considering recombination within
env. Thus, intact proviral NFL sequences found in the circulat-
ing reservoir may be able to contribute to rebound by re-
combination. Whether similar effects will also be seen in
individuals undergoing ATI in the absence of bNAb therapy
remains to be determined.
Recombination is a frequent occurrence during active in-
fection (27, 28). We are unable to determine directly whether the
recombinant viruses observed during ATI preexist in the reser-
voir or emerge during rebound. If they do preexist then they
must be very rare in circulation (<1%) and may be resident in
tissues such as the gut-associated lymphoid tissue (29). Cells
carrying these proviruses could be activated to produce them by
stimuli that are either unavailable to, or simply fail to activate
cells in the blood. For example, tissue resident CD4+ T cells in
the gut are exposed to far higher concentrations of bacterial
products than cells in circulation. However, VOAs and/or NFL
sequencing have not been performed on tissues from individuals
undergoing ATI and so this possibility remains speculative.
The alternative equally speculative idea is that latent provi-
ruses are generally unable to propagate robust infection in vivo,
and that establishment of proviral latency is facilitated by lower
overall viral fitness. According to this hypothesis, recombination
during rebound would facilitate selection of HIV-1 variants ca-
pable of producing robust viremia in vivo. The availability of
large numbers of latent and rebound HIV-1 viruses should en-
able the testing of this idea.
In conclusion, Q2VOA and NFL sequencing assays provide
complementary sets of information on HIV-1 proviruses in the
latent reservoir. However, the significance of this information in
assessing therapies aimed at HIV-1 cure is unclear and requires
further investigation (26). The results emphasize the importance
of ATI in evaluating therapies aimed at long-term remission or
cure of HIV-1 infection.
Materials and Methods
Study Subjects. Study participants were enrolled in an open-label phase 1b
study in which the combination of two anti–HIV-1 bNAbs were administered
during ATI (17). The protocol was approved by the Food and Drug Admin-
istration, the Paul Ehrlich Institute in Germany, and the Institutional Re-
view Boards at The Rockefeller University and the University of Cologne.
All participants provided written informed consent before participation
in the study and the study was conducted in accordance with Good
Clinical Practice.
Q2VOA. The Q2VOA was performed as previously described (5, 17).
Rebound Outgrowth Cultures. The rebound outgrowth cultures were per-
formed as previous described (17).
DNA Extraction and NFL HIV-1 Genome Sequencing. Peripheral blood mono-
nuclear cells (PBMCs) were obtained by leukapheresis at the preinfusion and
week 12. DNA was extracted from 1 to 10 × 106 CD4+ T cells using Qiagen
Gentra Purgene Cell Kit. Near full-length HIV-1 genome was generated as
previously described (11, 16, 20). Briefly, DNA was subjected to a limiting-
dilution gag PCR using 5′GagIn; 5′-GGGAAAAAATTCGGTTAAGGCC-3′ and 3′
GagIn 5′-CGAGGGGTCGTTGCCAAAGA-3′ in the first round and seminested
primer 3′GagInIn 5′-GGGGCTGTTGGCTCTGGT-3′ in the second round with
Platinum Taq polymerase (Invitrogen). Seminested gag PCR conditions were
94 °C for 2 min; 50 cycles of 94 °C for 30 s, 61 °C for 30 s, and 68 °C for 3 min;
and 68 °C for 10 min. PCR products were visualized and quantified using 1%
agarose gels. DNA dilutions wherein <30% of the gag PCR wells were pos-
itive, were selected for further analysis because they have more than an 80%
probability of containing a single copy of HIV DNA in each PCR based on the
Poisson distribution. NFL outer PCR was performed on DNA diluted to single
genome levels using Platinum Taq High Fidelity polymerase, and 1-μL ali-
quots were subjected to nested env PCR using envB5out 5′-TAGAGCCCTG-
GAAGCATCCAGGAAG-3′ and envB3out 5′-TTGCTACTTGTGATTGCTCCATGT-
3′ (5). NFL samples containing ∼3,000-bp amplicons were subjected to
four-segment PCR (A–D) (11) and then visualized on 0.7% agarose gels. If
the size of either segment A + C, A + D, B + C, or B + D was correct, two-
segment PCR products were combined and then subjected to library prep-
aration and sequencing (5). Paired-end reads were adapter trimmed and
filtered for quality with a Phred score cutoff of 10, using trimgalore
v0.4.1 and cutadapt v1.11. De novo assembly of the reads into scaffolds was
performed using SPAdes genome assembler v3.9.0. Scaffolds were then used
to find the closest HIV reference by BLAST, either against a local database of
HIV env annotations in the case of env assembly, or the National Center for
Biotechnology Information database in the case of full genome assembly.
The closest reference and the scaffolds are then assembled using Mira
v4.0.2 to generate an edited reference that more closely reflects the actual
sampled sequence. Finally, this edited reference is used as a backbone to
assemble the reads.
Identification of Intact Proviruses. Assembled sequences were aligned to the
HXB2 genome to identify premature stop codons, out-of-frame insertions or
deletions (indels), or packaging signal (Ψ) deletions and mutations using
custom Python scripts. Sequences containing productive genes and the MSD
site are classified as intact, while sequences with a mutated or deleted MSD
site are classified as Ψ-MSD deletion/mutation (SI Appendix, Fig. S8). Presence
of APOBEC-induced G–A hypermutation was determined in the remaining
intact NFL proviruses using the Los Alamos HIV Sequence Database Hypermut
tool. Sequences not classified as hypermutated are considered defective due
to indels/nonsense mutations (SI Appendix, Fig. S8). The frequency of intact
proviruses was calculated as the number of intact proviruses divided by the
total number of CD4+ T cells assayed.
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Comparisons of Different Reservoir Measurements. Fold change between
different reservoir measurements was based on the median fold change in
individual patients.
Construction of Phylogenetic Tree. Nucleotide alignments of intact env se-
quences were translation aligned using ClustalW v2.1 under the BLOSUM
cost matrix. Maximum likelihood phylogenetic trees were then generated
from these alignments with PhyML v3.1 using the general time-reversible
(GTR) model with 1,000 bootstraps. For the combined analysis of sequences
from all participants, env sequences were aligned using MAFFT v7.309 and
clustered using RAxML v8.2.9 under the GTRGAMMA model with 1,000
bootstraps. To analyze changes between reservoir and rebound viruses, env
sequences were aligned at the amino acid level to a HXB2 reference using
ClustalW v2.1.
Recombination Analysis of env Sequences. Multiple alignment of nucleotide
sequences guided by amino acid translations of env sequences was per-
formed by TranslatorX (translatorx.co.uk/). env sequences from Q2VOA, NFL,
and rebound sequences were analyzed for the presence of recombination
using the 3SEQ recombination algorithm (mol.ax/software/3seq/). Sequences
presenting statistical evidence of recombination (rejection of the null hy-
pothesis of clonal evolution) in which parent sequences were derived from
the latent reservoir and the “child” sequence was a rebound sequence are
represented in a circos plot (circos.ca/).
Simulation of Mutation Accumulation During Rebound. The differences be-
tween rebound and NFL/Q2VOA sequences were analyzed using the
stochastic mutation simulation model as previously described (16). The
expected number of mutations accumulated during rebound was cal-
culated taking into consideration the time to rebound.
Statistical Analyses. Statistical analyses were performed using GraphPad
Prism 7.0a for Mac OS X.
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